



# FORM: IRB Reliance Agreement



Document No.:	Edition No.:	Effective Date:	Page:
HRP-235	001.2	21 Jun 2022	Page 1 of 3

Complete this form when a local IRB has jurisdiction over this research site.

You must submit a typed version of this form (except for the signature block) to prevent errors and delays due to legibility problems.

**Blank & incomplete answers will result in delayed reviews**

If you have questions about the use of this form, please contact WCG IRB at 855-818-2289 or email [clientcare@wcgirb.com](mailto:clientcare@wcgirb.com)

### Relying Organization:

Name: University of Chicago BSD-IRB

FWA #: 00005565 (if organization has an FWA)

### Contact Information for Relying Organization:

Name: Jeremy LaVigne, MA, CIP

Title: IRB Reliance Manager

Address 1: University of Chicago

Address 2: 5841 South Maryland

City: Chicago

State/Province: IL

Zip/Postal Code: 60637

Country: USA

Phone: (773) 834-8262

Email: [jlavigne@bsd.uchicago.edu](mailto:jlavigne@bsd.uchicago.edu)

This agreement covers all human subjects research conducted by this site (otherwise complete the "Research Protocol" and "Principal Investigator" sections below)

### Research Protocol:

Protocol #: None

Protocol Title: Understanding HIV/STD Risk and Enhancing PrEP Implementation Messaging in a Diverse Community-Based Sample of Gay, Bisexual, and Other Men Who Have Sex with Men in a Transformational Era (MIC-DROP)

Sponsor Name: Centers for Disease Control and Prevention

IRB Tracking #: 20225896 (if known)

### Principal Investigator:

Name: John Schneider, MD

The Relying Organization agrees to waive jurisdiction for the IRB review and continuing oversight of the Research Protocol to WCG IRB (IRB registration number IRB00000533) ("Designated IRB") as allowed under federal regulations. The Principal Investigator is authorized to conduct the Research Protocol at the Relying Organization.

The review performed by the Designated IRB will meet the human subject protection program requirements of applicable regulatory agencies. The Designated IRB will follow its written procedures for the review and oversight of the Research Protocol. The Designated IRB will follow its written procedures for reporting findings and actions, subject complaints, unanticipated problems involving risks to subjects or others, serious or continuing noncompliance, and suspension or termination to appropriate institutional officials at the Relying Organization. Relevant minutes of IRB meetings will be made available to the Relying Organization upon request. Relying Organization remains responsible for ensuring compliance with the Designated IRB's determinations and with the terms of any



<b>FORM: IRB Reliance Agreement</b>			
<b>Document No.:</b>	<b>Edition No.:</b>	<b>Effective Date:</b>	<b>Page:</b>
<b>HRP-235</b>	<b>001.2</b>	<b>21 Jun 2022</b>	<b>Page 2 of 3</b>



agreements between the Relying Organization and applicable regulatory agencies. This document must be kept on file by both parties and provided to applicable regulatory agencies upon request.



# FORM: IRB Reliance Agreement



Document No.:	Edition No.:	Effective Date:	Page:
HRP-235	001.2	21 Jun 2022	Page 3 of 3

### For Designated IRB

DocuSigned by:

*Bridget Brave*

Signature



Signer Name: Bridget Brave  
Signing Reason: I have reviewed this document  
Signing Time: 18-Aug-2023 | 11:00:58 AM EDT

Printed Name

B411625B7E52430E874F4E13BFF1865C

Director, Expedited Review

Title

18-Aug-2023 | 11:01:01 AM EDT

Date

### For Relying Organization

*Jennifer A Ponting*

Signature

Jennifer A Ponting

Printed Name

Associate Vice President for Research, Director of University  
Research Administration

Title

8/10/23

Date